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Background/aim: Coronavirus 2019 disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
is a pandemic infectious disease that causes morbidity and mortality. As a result of high mortality rate among the severe COVID-19
patients, the early detection of the disease stage and early effective interventions are very important in reducing mortality. Hence, it is
important to differentiate severe and nonsevere cases from each other. To date, there are no proven diagnostic or prognostic parameters
that can be used in this manner. Due to the expensive and not easily accessible tests that are performed for COVID-19, researchers are
investigating some parameters that can be easily used. In some recent studies, hematological parameters have been evaluated to see if
they can be used as predictive parameters.
Materials and methods: In the current study, almost all hematological parameters were used, including the neutrophil/lymphocyte
ratio, platelet/lymphocyte ratio, monocyte/lymphocyte ratio, mean platelet volume to lymphocyte ratio, mean platelet volume to platelet
ratio, plateletcrit, and D-dimer/fibrinogen ratio, neutrophil/lymphocyte/platelet scoring system, and systemic immune-inflammation
index. A total of 750 patients, who were admitted to Ankara City Hospital due to COVID-19, were evaluated in this study. The patients
were classified into 2 groups according to their diagnosis (confirmed or probable) and into 2 groups according to the stage of the disease
(nonsevere or severe).
Results: The values of the combinations of inflammatory markers and other hematological parameters in all of the patients with severe
COVID-19 were calculated, and the predicted values of these parameters were compared. According to results of the study, nearly all
of the hematological parameters could be used as potential diagnostic biomarkers for subsequent analysis, because the area under the
curve (AUC) was higher than 0.50, especially for the DFR and NLR, which had the highest AUC among the parameters.
Conclusion: Our findings indicate that, the parameters those enhanced from complete blood count, which is a simple laboratory test,
can help to identify and classify COVID-19 patients into non-severe to severe groups.
Key words: COVID-19, SARS-CoV-2, hematological tests, predictive values of tests

1. Introduction
Coronavirus 2019 disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
is a pandemic infectious disease that causes morbidity
and mortality. To date there are no proven diagnostic or
prognostic parameters, but clinicians can use predictive
parameters, such as the leukocyte and lymphocyte counts,

C-reactive protein (CRP), D-dimer, and ferritin levels, and
radiological imaging [1-3]. In the inflammation process of
COVID-19, CRP, platelet, ferritin, and leukocyte values
may increase, while albumin and lymphocyte values may
decrease [4-6].
White blood cells (WBCs), including neutrophils,
lymphocytes, monocytes, have been used as inflammatory
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biomarkers in infections, autoinflammatory diseases, and
cancers that contain inflammatory processes, and are the
most generally performed laboratory tests [5-8].
The neutrophil/lymphocyte ratio (NLR) is a strong
biomarker, indicating acute and chronic inflammatory
status, is reliable, cost-effective, and easily applicable, and
is considered as a stronger inflammatory marker than
the individual assessment of the neutrophil count or
lymphocyte count [7-10]. The platelet/lymphocyte ratio
(PLR), monocyte/lymphocyte ratio (MLR), mean platelet
volume/lymphocyte ratio (MPVLR), mean platelet
volume/platelet ratio (MPVPR) are the parameters that
are easily calculated from the complete blood count.
Earlier studies have shown that these parameters have
prognostic value for various diseases, in addition to the
early recognition of infection and inflammation [3,11,12].
One of the newly introduced parameters to measure
the degree of inflammation is the systemic immuneinflammation index (SII). This index is obtained by
multiplying the platelet count by the NLR [13-15]. The SII
has been accepted as an indicator of inflammatory status,
with the added feature of being a prognostic marker in
malignancy [3,13-15].
Scoring systems with predictive value that have
been developed using hematological parameters are
also important. An example of this is the neutrophil/
lymphocyte/platelet scoring system (NLP score). Studies
using this scoring system found that COVID-19 patients
with an NLP score greater than 6 had a high risk of severe
disease [10].
D-dimer is a fibrin degradation product and has
been specifically associated with secondary fibrinolysis.
However, fibrinogen is a coagulation product synthesized
from the liver, and it is also an acute phase reactant. In
previous studies, the D-dimer/fibrinogen ratio (DFR) was
found to be significantly correlated with inflammation,
malignancy, and thromboembolic events [16-20]. The
mechanism responsible for the inclusion of hematological
parameters in this process is the effects of cytokines
and chemokines released from neutrophils, monocytes,
and macrophages migrating to the inflammation site, in
addition, the fact that the reactive oxygen species, caused
by lysosomal enzymes released from neutrophils, cause
the immature, young erythrocytes and platelets to enter
peripheral circulation from the bone marrow [7].
Hematological parameters are important to support
the diagnosis of COVID-19. The aim in this study was
to evaluate the relationship of hematological parameters
(NLR, PLR, MLR, MPVLR, DFR, MPVPR, plateletcrit,
NLP score, and SII) with confirmed and probable
COVID-19 cases. In addition, it was aimed to evaluate
whether these biomarkers predicted the severity of

the disease with the first-look values in the emergency
department (ED) in COVID-19 patients. There are studies
that have evaluated whether one or more hematological
parameters can predict severe disease in COVID-19, but
the current study was the first in which almost all of the
hematological parameters were evaluated together.
2. Materials and methods
This study was conducted at the Internal Medicine and
Infectious Diseases wards of Ankara City Hospital
due to COVID-19, and the patients were evaluated
retrospectively. Patients younger than 18 years of age,
those with active malignancy, and pregnant women were
excluded from the study. Ethical approval for the study
was obtained from the Ethics Committee of Ankara
City Hospital (approval number: E1-20-999). The age,
sex, comorbidity, and medications of the patients, as
well as the D-dimer, fibrinogen, complete blood count,
biochemical parameters, CRP, sedimentation, and
thorax computerized tomography (CT) findings on the
ED admission were recorded. Demographic, clinical,
laboratory, imaging examination, treatment, and outcome
data were collected using a standardized case-report form.
All data were checked by 2 physicians (MD and RC), and
then a third researcher (BK) determined any differences
in interpretation between the 2 primary reviewers.
To understand the relation with disease severity,
9 inflammatory markers were used. Moreover, 9
inflammatory factors, including the NLR, PLR, MLR,
MPVLR, MPVPR, plateletcrit, DFR, NLP, and SII (platelet
× neutrophil/lymphocyte) were used in this analysis.
From all of the patients, nasal and/or pharyngeal
swab specimens were collected, and reverse-transcriptase
polymerase chain reaction (RT-PCR) assays were
performed. The diagnosis of COVID-19 was based on
positivity of the real-time RT-PCR results.
According to the diagnosis, the patients were classified
into 2 groups, as confirmed and probable COVID-19
(Figure). According to the stage of the disease, the first
group comprised non-severe patients who had any of
the following: slight symptoms, fever, respiratory tract
symptoms, and no radiological findings or pneumonia
findings on radiological examination. The second group
comprised severe patients who had any of the following:
tachypnea with a respiration rate >30 beats/min, resting
oxygen saturation < 92%, arterial partial oxygen pressure
(PaO2)/fraction of inspired oxygen (FiO2) < 301 mmHg,
radiological aggravation greater than 50% within 24–48
h, respiratory failure and mechanical ventilation, shock,
and organ failure requiring intensive care unit admission.
To determine severe patients on admission to the hospital
for a respiratory illness, the slightly modified and adopted
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According to the diagnosis

PCR (+)

PCR (–)

Confirmed COVID-19

Any 2 of the 3 features:
-History (+)
-Symptom (+)
-Radiological finding (+)

Probable COVID-19
Figure. Diagram of distinction COVID-19 patients as confirmed and probable.

interim guidance of the World Health Organization1
was used [21]. The outcome of the follow-up was the
occurrence of severe illness, and the end of follow-up time
was 1st of June 2020.
Hospitalization, treatment, management, and
discharge decisions of the patients were made according to
the guidelines of the Turkish Ministry of Health2.
3. Statistical analysis
The data were analyzed using IBM SPSS for Windows
v: 25.0 (IBM Corp., Armonk, NY, USA) and MedCalc
15.8 (Franz Faul, Universitat Kiel, Germany). While the
frequency, percentage, mean, standard deviation, median,
and IQR were used as descriptive statistical methods, the
chi square (c2) test was used to compare the qualitative
data. The consistency of the data to normal distribution
was evaluated using the Kolmogorov–Smirnov and
Shapiro–Wilk tests. The Mann–Whitney U test was used
to compare the nonnormally distributed data. While the
receiver operating characteristic (ROC) curve method
was used to determine the discrimination of the variables,
binary logistic regression was used to determine the risk
rates. Statistical significance was accepted as p < 0.05.
4. Results

Of the 750 patients included in the study, 388 (51.7%) were
confirmed COVID-19 patients, while 362 (48.3%) were
probable COVID-19 patients. Of these 750 patients, 442
(58.9%) were males. The median (IQR) age of all of the
patients was 49 (28) years (Table 1). The median (IQR) age
in the probable group was 55 (27) years, while it was 45
(25) years in the confirmed group (p < 0.0001).
The frequency of cough, fever, myalgia, anosmia,
ageusia, and arthralgia was significantly higher in the
confirmed group than in the probable group (Table 1).
The frequency of dyspnea was significantly higher in the
probable group than in the confirmed group. There was
no statistically significant difference between the probable
and confirmed groups in terms of headache, nausea,
diarrhea, back pain, or abdominal pain.
The frequency of smoking and any comorbidity was
significantly higher in the probable group than in the
confirmed group (p = 0.008 and p < 0.0001). While the
need for intensive care was higher in the probable group
(p < 0.0001), mortality was higher in the confirmed group
(p < 0.0001).
Considering the indices, the MPV/lymphocyte ratio
and the MPV/platelet ratio were significantly higher in the
confirmed group than in the probable group (p < 0.0001)

World Health Organization (2020). Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is
Probable. Interim Guidance, 13 March 2020 [Online]. Website: https://apps.who.int/iris/handle/10665/330854 [accessed 14 April 2020].
1

Republic of Turkey Ministry of Health Directorate General of Public Health (2020). COVID-19 (SARS-CoV-2 Infection) guide (in Turkish) [online].
Website: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 14 April 2020].
2
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Table 1. Evaluation of the confirmed and probable patients according to clinical status, demographics, past-history, and laboratory
parameters other than hematological parameters.
Characteristics or findings

All patients
n: 750

Confirmed diagnosis
n: 388

Probable disease
n: 362

*P-value

Male sex, no. (%)

442 (58.9)

219 (56.4)

223 (61.6)

0.151

Median age, (IQR) years

49 (28)

45 (25)

55 (27)

<0.0001

Cough, no. (%)

396 (52.8)

227 (58.5)

169 (46.7)

0.001

Fever, no. (%)

284 (37.9)

179 (46.1)

105 (29.0)

<0.0001

Dyspnea, no. (%)

219 (29.2)

87 (22.4)

132 (36.5)

<0.0001

Headache, no. (%)

69 (9.2)

41 (10.6)

28 (7.7)

0.180

Nausea, no. (%)

47 (6.3)

29 (7.5)

18 (5)

0.207

Myalgia, no. (%)

166 (22.1)

109 (28.1)

57 (15.7)

<0.0001

Diarrhea, no. (%)

43 (5.7)

24 (6.2)

19 (5.2)

0.693

Back pain, no. (%)

3 (0.4)

2 (0.5)

1 (0.3)

1.000

Anosmia, no. (%)

37 (4.9)

26 (6.7)

11 (3)

0.032

Ageusia, no. (%)

33 (4.4)

243 (6.2)

9 (2.5)

0.022

Abdominal pain, no. (%)

11 (1.5)

2 (0.5)

9 (2.5)

0.052

Arthralgia, no. (%)

25 (3.3)

19 (4.9)

6 (1.7)

0.023

Smoking (smoker and nonsmoker), no. (%)

66 (29.5)

21 (20.6)

45 (36.9)

0.008

Any comorbidity, no. (%)

307 (40.9)

119 (30.7)

188 (51.9)

<0.0001

Hypertension, no. (%)

197 (26.3)

74 (19.1)

123 (34)

<0.0001

Diabetes, no. (%)

129 (17.2)

51 (13.1)

78 (21.5)

0.002

Asthma, no. (%)

42 (5.6)

16 (4.1)

26 (7.2)

0.097

Obesity, no. (%)

4 (0.5)

4 (1.0)

0 (0)

0.125

Coronary heart disease, no. (%)

111 (14.8)

31 (8.0)

80 (22.1)

<0.0001

Renal disease, no. (%)

37 (4.9)

6 (1.5)

31 (8.6)

<0.0001

COPD, no. (%)

37 (4.9)

9 (2.3)

28 (7.7)

0.001

Intensive care unit, no. (%)

119 (15.9)

44 (11.3)

75 (20.7)

<0.0001

Deceased, no. (%)

728 (97.1)

13 (3.4)

9 (2.5)

<0.0001

Creatin (mg/dL)

0.81 (0.29)

0.81 (0.27)

0.84 (0.33)

0.046

Lactate dehydrogenase (U/L)

225 (95.5)

218.5 (87.5)

236 (115)

0.002

C-reactive protein (g/L)

0.01 (0.04)

0.01 (0.02)

0.01 (0.05)

0.001

ESR (mm/h)

22 (36)

18 (31)

24 (42.25)

0.126

Ferritin concentration (µg/L)

127.5 (212.75)

122 (244.5)

134 (207.5)

0.357

COPD: chronic obstructive pulmonary disease, ESR: erythrocyte sedimentation rate.
*Statistical evaluations were made between probable and confirmed COVID-19 patients. All laboratory parameters were calculated as
the median (IQR).

(Table 2). The NLR and SII scores were significantly higher
in the probable group than in the confirmed group (Table 2).
Detailed comparison of hematological parameters in
terms of severity vs nonseverity in all 3 groups (all patients,
confirmed group, and probable group) is shown in Table
3. Severe disease patients in all 3 groups (all patients,
confirmed group, and probable group) were older than the
non-severe patients (p < 0.0001). In all 3 groups, severe

disease patients had more comorbidities than the nonsevere patients (p < 0.0001). Except for 1 (MPV/platelet
ratio) of the 8 indices (NLR, excluding the PLR, MLR,
MPV/lymphocyte, MPV/platelet ratio, and DFR, and SII
and NLP scores), all of the indices showed a statistically
significant differences in terms of severity of the disease
between the 3 groups (Table 3).
The multivariate logistic regression model for severe
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Table 2. Evaluation of the hematological parameters between the confirmed and probable patients at the time of admission.
Parameters

All patients
n: 750

Confirmed diagnosis
n: 388

Probable disease
n: 362

*P-value

WBC (10^9/L)

6.14 (3.43)

5.15 (2.48)

7.1 (3.9)

<0.0001

Neutrophil count (10^9/L)

3.90 (2.60)

3.30 (1.97)

4.66 (3.38)

<0.0001

Lymphocyte count (10^9/L)

1.38 (0.92)

1.25 (0.71)

1.5 (1.12)

<0.0001

Monocyte count (10^9/L)

0.4 (0.22)

0.35 (0.20)

0.43 (0.29)

<0.0001

Hemoglobin (g/dL)

13.6 (2.5)

13.8 (2.3)

13.4 (2.63)

0.031

Mpv (fL)

8.10 (1.35)

8.2 (1.2)

7.9 (1.3)

<0.0001

Plateletcrit (%)

0.2 (0.12)

0.18 (0.09)

0.22 (0.19)

<0.0001

Platelet (10^9/L)

231 (107)

209 (97.75)

249.5 (114.5)

<0.0001

NLR

2.65 (2.69)

2.45 (2.24)

2.98 (3.42)

<0.0001

PLR

166 (119.62)

167.04 (116.15)

163.10 (122)

0.388

LMR

3.67 (2.68)

3.66 (2.57)

3.70 (2.84)

0.900

MPVLR

5.83 (4.49)

6.63 (4.08)

4.61 (4.25)

<0.0001

MPVPR

0.03 (0.03)

0.04 (0.02)

0.03 (0.02)

<0.0001

Fibrinogen concentration (g/L)

3.5 (1.7)

3.36 (1.54)

3.8 (1.98)

<0.0001

D-dimer (mg/L)

0.5 (0.78)

0.43 (0.54)

0.61 (1.07)

<0.0001

DFR

0.14 (0.18)

0.14 (0.14)

0.15 (0.26)

0.002

SII

615.91 (759.52)

516.39 (557.09)

752.44 (982.55)

<0.0001

NLP score

4 (4)

4 (4)

4 (4)

0.002

WBC: white blood cell count, MPV: mean platelet volume, NLR: neutrophil/lymphocyte ratio, PLR: platelet/lymphocyte ratio, LMR:
lymphocyte/monocyte ratio, MPVLR: MPV/lymphocyte ratio, MPVPR: MPV/platelet ratio, DFR: D-dimer/fibrinogen ratio, SII:
systemic immune-inflammation index, N/LP: neutrophil/lymphocyte-platelet.
*Statistical evaluation were made between confirmed and probable patients. All laboratory parameters were calculated as median (IQR).

disease consisted of the variables, including age, male sex,
plateletcrit, NLR, PLR, MLR, MPV/lymphocyte, MPV/
platelet, and DFR, and SII and NLP scores which are given
in Table 4. In the multivariate logistic regression analyses,
DFR in the highest tertile (HR: 1.206, 95% CI: 1.049–1.387,
p = 0.009) was determined as an independent predictor of
severe disease in COVID-19. In the multivariate analyses,
the serum plateletcrit value, NLR, PLR, and age were
found to be an independent predictor of severe disease in
COVID-19.
The values of 8 combinations of inflammatory
markers and other hematological parameters in all of the
patients with severe COVID-19 were calculated, and the
predicted values of these parameters were compared in
the ROC analysis. In Table 5, area under the curve (AUC)
of the DFR, NLR, and SII were 0.767, 0.750, and 0.740,
respectively. The optimal cut-off values were >0.22, >3.59,
and >998.28 for the DFR, NLR, and SII, respectively.
Nearly all of the hematological parameters could be used
as potential diagnostic biomarkers for subsequent analysis
because their AUC was higher than 0.50.
5. Discussion

2814

Laboratory medicine has a crucial role in the diagnosis
and management of variable diseases [22]. Recent studies
have reported the routine blood test results of COVID-19
patients and shown the differences between the nonsevere
and severe COVID-19 patients [21-23-24]. Subtypes of
the WBCs alone are good predictors of inflammation
but the NLR is superior to them because it combines the
value of 2 subtypes [8]. For COVID-19, it is known that
the lymphocyte count decreases, thus the NLR becomes
valuable in this situation. Inflammatory storm and severity
of COVID-19 have a close relation [25], and as a result,
prognosis of the disease can be better reflected using the
NLR. Among patients diagnosed with COVID-19, it was
found that patients with severe symptoms had a higher
NLR than patients with mild-to-moderate symptoms.
High NLR levels promote COVID-19 progression.
According to this study, an increased NLR on admission
was accepted as an independent risk factor for severe cases
of COVID-19. In a meta‑analysis, it was shown that the
neutrophil count and NLR were positively correlated and
the lymphocyte count was negatively correlated to the
severity of COVID-19 [26]. Hence, NLR is a significant

Table 3. Evaluation of the hematological parameters among the confirmed, probable, and all patients according to the severity of the disease at the time of admission.
All patients

Probable disease

Confirmed diagnosis

Nonsevere
n: 631

Severe
n: 119

P-value

Nonsevere
n: 287

Severe
n: 75

P-value

Nonsevere
n: 344

Severe
n: 44

P-value

Male sex

371 (58.8)

71 (59.7)

0.86

179 (62.4)

44 (58.7)

0.55

192 (55.8)

27 (61.4)

0.59

Age, years

46 (25)

67 (18)

<0.0001 50 (24)

67 (20)

<0.0001

42 (23)

67.5 (13.75)

<0.0001

Any comorbidity

224 (35.5)

83 (69.7)

<0.0001 131 (45.6)

57 (76)

<0.0001

93 (27)

26 (59.1)

<0.0001

WBC (10^9/L)

5.86 (3.08)

7.70 (5.42)

<0.0001 6.98 (3.60)

8.11 (5.9)

0.008

5.1 (2.25)

6.52 (3.97)

<0.0001

Neutrophil count (10^9/L)

3.62 (2.28)

5.42 (4.61)

<0.0001 4.47 (2.56)

6.12 (5.35)

<0.0001

3.18 (1.77)

4.78 (3.86)

<0.0001

Lymphocyte count (10^9/L)

1.42 (0.96)

1.08 (0.67)

<0.0001 1.65 (1.09)

1.15 (0.76)

<0.0001

1.30 (0.72)

1.00 (0.53)

<0.0001

Monocyte count (10^9/L)

0.39 (0.21)

0.41 (0.3)

0.122

0.47 (0.34)

0.484

0.35 (0.21)

0.40 (0.22)

0.407

Hemoglobin (g/dL)

13.8 (2.3)

12.1 (2.8)

<0.0001 13.7 (2.4)

12 (2.9)

<0.0001

13.9 (2.2)

12.3 (2.9)

<0.0001

Mpv (fL)

8 (1.3)

8.3 (1.7)

0.031

7.9 (1.33)

8.1 (1.4)

0.271

8.2 (1.2)

8.6 (1.75)

0.003

Plateletcrit (%)

0.2 (0.1)

0.24 (24.24)

0.008

0.22 (0.18)

0.24 (0.22)

0.708

0.18 (0.09)

0.23 (31.93)

0.02

Platelet (10^9/L)

230 (103)

235 (178)

0.321

249 (108)

254 (173)

0.642

210 (96)

199.5 (127)

0.95

NLR

2.43 (2.05)

5.43 (5.36)

<0.0001 2.57 (2.45)

5.59 (5.19)

<0.0001

2.34 (1.83)

5.05 (5.72)

<0.0001

PLR

157.82 (104.95) 216.5 (237.38)

<0.0001 151.18 (105.14) 206.22 (240.21)

<0.0001

160.31 (106.74) 241.2 (233.81)

<0.0001

LMR

3.88 (2.72)

2.59 (2.13)

<0.0001 4.05 (2.85)

2.67 (2.22)

<0.0001

3.74 (2.55)

2.52 (1.99)

<0.0001

MPVLR

5.62 (4.05)

7.33 (6.1)

<0.0001 4.42 (3.79)

6.17 (6.04)

0.001

6.42 (4.01)

8.84 (5.5)

<0.0001

MPVPR

0.03 (0.02)

0.42 (0.26)

0.03 (0.03)

0.642

0.03 (0.02)

0.775

0.04 (0.02)

0.04 (0.03)

0.453

Fibrinogen concentration (g/L) 3.39 (1.6)

4.37 (2.65)

<0.0001 3.6 (1.78)

4.48 (3.35)

<0.0001

3.22 (1.47)

4.1 (1.96)

<0.0001

D-dimer (mg/L)

0.43 (0.54)

1.60 (2.84)

<0.0001 0.48 (0.72)

1.82 (2.72)

<0.0001

0.40 (0.43)

1.17 (2.97)

<0.0001

DFR

0.13 (0.13)

0.37 (0.81)

<0.0001 0.13 (0.18)

0.38 (0.88)

<0.0001

0.12 (0.11)

0.32 (0.83)

<0.0001

SII

550.48 (598.67) 1.358.94 (1.887.2) <0.0001 643.07 (729.72) 1.455.50 (2.030.06) <0.0001

485.63 (451.77) 1.161.77 (1.829.86) <0.0001

NLP score

4 (4)

4 (4)

4 (4)

0.03 (0.02)

<0.0001 4 (4)

4 (4)

<0.0001

4 (7)

<0.0001

Abbreviations: WBC; White blood cell count, MPV; Mean platelet volume, NLR; Neutrophil/lymphocyte ratio, PLR; Platelet/lymphocyte ratio, LMR; Lymphocyte/monocyte ratio,
MPVLR; MPV/lymphocyte ratio, MPVPR; MPV/platelet ratio, DFR; D-dimer/fibrinogen ratio, SII; Systemic immun-inflammation index, NLP score; Neutrophil-lymphocyteplatelet score
All laboratory parameters have been calculated as median (IQR).
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Table 4. Evaluation of the hematological parameters of all of the
patients according to the severity of disease with multivariate
logistic regression analyses at the time of admission.

Parameters

All patients
OR

95% CI

P-value

Male sex

1.213

0.748–1.967

0.434

Age, years

1.071

1.055–1.088

<0.0001

Any comorbidity

1.304

0.763–2.227

0.332

Plateletcrit (%)

1.015

1.000–1.030

0.049

NLR

1.076

1.028–1.127

0.002

PLR

1.002

1.000–1.004

0.027

LMR

0.995

0.960–1.031

0.776

MPVLR

0.989

0.930–1.051

0.718

MPVPR

1.005

0.778–1.299

0.970

DFR

1.206

1.049–1.387

0.009

SII

1.000

1.000–1.000

0.556

NLP score

1.044

0.948–1.149

0.383

Abbreviations: WBC; White blood cell count, MPV; Mean platelet
volume, NLR; Neutrophil/lymphocyte ratio, PLR; Platelet/
lymphocyte ratio, LMR; Lymphocyte/monocyte ratio, MPVLR;
MPV/lymphocyte ratio, MPVPR; MPV/platelet ratio, DFR;
D-dimer/fibrinogen ratio, SII; Systemic immun-inflammation
index, NLP score; Neutrophil-lymphocyte-platelet score.

and valuable parameter in determining the severity of the
disease.
Platelets, i.e. the lymphocyte count, are also correlated
with inflammation. In COVID-19 the lower lymphocyte
count was correlated with an increased risk of inflammation
[27].
PLR has been recently used to predict prognosis of
thrombotic and inflammatory diseases. Since COVID-19
has an inflammatory process, and in many cases,
thrombotic events have been reported, PLR was thought
to have the potential to show the prognosis of COVID-19
[28]. Some recent studies have shown higher PLR levels in
severe COVID-19 patients when compared to non-severe
patients [29,30]. In the current study, it was found that the
PLR value measured on admission increased in parallel
with the progression of severity. Hence, increased PLR on
admission was accepted as an independent risk factor for
severe cases of COVID-19 in this study.
As for the other WBC subtypes, the monocyte count
is also related with inflammation and is expected to be
elevated [31]. Recently, some new indicators of disease
severity have been used, such as the MLR, and they were
related with various diseases like rheumatic disease and
cancer [7-32]. In one study, the MLR was demonstrated as
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to be the best marker of infection in cirrhotic patients [33].
In another study, among COVID-19 patients who showed
progression on chest CT scan, the MLR was dramatically
higher when compared to the other markers, such as
the aspartate aminotransferase-lymphocyte ratio index,
aspartate aminotransferase-platelet ratio index, NLR, PLR,
and SII [34]. Similarly, in the current study, the MLR was
significantly higher in the severe disease patient group
than in the non-severe patient group, but the MLR on
admission was not accepted as an independent risk factor
for severe cases of COVID-19.
Platelet function and activation is reflected by the MPV,
and it could be used as a marker for inflammation [35]. The
MPV is also a valuable marker in systemic inflammatory
diseases and is thought to have a parallel correlation with
CRP [36]. MPV levels have shown depressed levels during
systemic inflammatory situations [37]. The mechanism for
this is still unclear, but during the inflammatory process,
a defect in thrombopoiesis could be responsible for this
situation [12].
In another study, it was reported that the MPVLR
could be used as a new marker for inflammatory diseases
and thrombotic events [38,39].
The data obtained herein from the COVID-19
patients were similar to those of previous studies, and it is
suggested that the MPVLR can be used as a new parameter
to determine disease severity groups. However, it is not an
independent risk factor for severe cases of COVID-19,
according to the results of the current study.
Hypercoagulability is a common finding among
severe COVID-19 cases [40]. This is the main reason why
thromboembolic events have been seen so frequently in
severe COVID-19 patients [41,42]. As other blood cell
platelets are also affected by core inflammatory cytokines,
such as interleukin (IL)-1, IL-6, INF-γ, and tumor necrosis
factor, they have a close relationship with inflammation,
and that is why they were accepted herein as acute phase
reactant [43]. In some studies, MPVPR levels have been
found to be higher in various patients who had inflammatory
process like sepsis and pancreatitis. Additionally, increased
thrombosis and mortality were reported in Behçet disease
[44-46]. Among the English literature on the MPVPCR in
COVID-19, the current study is unique with its findings.
Contrary to other studies, MPVPCR was not found to be
a significant marker to classify COVID-19 patients into
severe or nonsevere groups.
In blood, the percentage of platelet volume is defined
by the plateletcrit. Recent studies have reported that
plateletcrit may be a more effective marker compared to
MPV [11,47,48]. The plateletcrit has been shown to be
increased and associated with CRP and d-dimer levels in
active inflammation [49].
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Table 5. AUC and optimal thresholds of each independent risk or protection factors for the hematological parameters of all of the
patients according to the severity of the disease.
Indicators

AUC

P-value

Optimal
threshold

Sensitivity

Specificity

Youden
index

WBC (10^9/L)

0.653

<0.0001

>7.69

50.42

74.17

0.246

Neutrophil count (10^9/L)

0.702

<0.0001

>4.7

62.18

70.05

0.322

Lymphocyte count (10^9/L)

0.664

<0.0001

≤1.11

57.98

69.05

0.270

Monocyte count (10^9/L)

0.545

0.137

>0.39

60.5

51.43

0.119

Hemoglobin (g/dL)

0.708

<0.0001

≤12.8

66.39

71.16

0.375

Mpv (fL)

0.562

0.043

>8.9

30.25

82.22

0.125

Plateletcrit (%)

0.577

0.013

>0.28

43.70

78.73

0.224

Platelet (10^9/L)

0.529

0.385

>335

29.41

87.96

0.174

NLR

0.750

<0.0001

>3.59

70.59

71.43

0.420

PLR

0.661

<0.0001

>279.07

42.02

86.67

0.287

LMR

0.689

<0.0001

≤3.08

65.55

65.56

0.311

MPVLR

0.620

<0.0001

>6.91

57.98

66.35

0.243

MPVPR

0.513

0.676

≤0.02

34.45

76.83

0.113

Fibrinogen concentration (g/L)

0.684

<0.0001

>4.34

50.42

78.13

0.286

DFR

0.767

<0.0001

>0.22

67.23

75.75

0.430

SII

0.740

<0.0001

>998.28

63.87

76.35

0.402

NLP score

0.665

<0.0001

6

32.8

86.7

0.246

Abbreviations: WBC; White blood cell count, MPV; Mean platelet volume, NLR; Neutrophil/lymphocyte ratio, PLR; Platelet/lymphocyte
ratio, LMR; Lymphocyte/monocyte ratio, MPVLR; MPV/Lymphocyte ratio, MPVPR; MPV/platelet ratio, DFR; D-dimer/fibrinogen
ratio, SII; Systemic immun-inflammation index, NLP score; Neutrophil-lymphocyte-platelet score.

The plateletcrit was significantly higher in the severe
group when compared to all of the patients, as severe vs.
non-severe. It is an independent risk factor for severe cases
of COVID-19 according to the current study. Considering
the studies showing that plateletcrit increases in active
inflammation, the results of the present study were not
surprising.
Fibrinogen levels increase as an acute phase reactant
in various diseases that have inflammatory processes,
such as hemodynamic impairments, cardiac-lung-aortic
diseases, infections, and malignancies [50]. During this
pandemic, many studies have reported thrombotic and
thromboembolic events among COVID-19 patients,
wherein the patients had elevated d-dimer and fibrinogen
levels and decreased antithrombin levels [51]. In patients
with infection or sepsis that was diagnosed in the ED, a
relationship was found between high levels of d-dimer
and 28-day mortality [52]. In another study, it was shown
that poor prognosis and fatality were more common
in COVID-19 patients if the d-dimer levels were higher
than 1 µg/mL [53]. Earlier studies have reported that the
DFR has the potential to be a predictor for thrombotic/
thromboembolic events, stroke, and gastrointestinal

stromal tumors [16-19]. The theory about the coagulation
cascade is that when the system is activated to form fibrin
in the pulmonary vasculature, fibrinogen is degraded
into products, such as D-dimer, leading these products
to be elevated in the bloodstream [54]. This theory may
be applicable in COVID-19, without complications that
may influence the DFR (as an acute-phase reactant) on
admission to the ED. It was found herein that patients with
a high FDR had poor prognosis. According to the results
of the multivariate analysis, the FDR can be used as a good
parameter for predicting severity in COVID-19 patients.
The NLP score was calculated for the COVID-19
patients, and the results showed that, if the score was
higher than 6, the risk for progression to a severe disease
was increased [6]. In terms of the NLP, the results obtained
were similar to those of previous studies in the severe
disease group. In this respect, the NLP score may be one of
the important new parameters in terms of showing poor
prognosis in COVID-19 patients. However, it was not
found it as an independent risk factor in the current study.
Among the COVID-19 patients, those who had a NLP
score higher than 6 required more attention in terms of
progression to severe disease. In this study, the specificity
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of a NLP score greater than 6 in predicting severe disease
was 86.7%.
The SII is a tool that uses and combines 3 separate
factors, comprising the neutrophil, lymphocyte, and
platelet counts. In some studies, this parameter was
used for the prediction of recurrency and survival in
many solid tumors as a systemic inflammatory indicator
[55,56]. In a recent study that was performed during the
COVID-19 pandemic, it was reported that there was a
positive correlation between the SII and the severity of the
disease. In the current study, the calculated SII values were
significantly higher in the severe disease group. The SII
may be used as a new parameter with prognostic value in
COVID-19 patients.
The diagnosis of COVID-19 is mainly confirmed
with RT-PCR assays, depending on the detection of the
SARS-CoV-2 virus [57], on the other hand for probable
COVID-19 patients, primarily clinical, radiographic, and
epidemiological features have importance on the initial
medical examination [58]. Significant results were obtained
when comparing the confirmed and probable groups of
COVID-19 patients. Dyspnea was significantly higher in
the probable patient group than in the confirmed patient
group. This result was not surprising considering that one
of the inclusion criteria in the probable patient group was
radiological examination. In addition, while the patients in
the probable group were older, smoking and comorbidities
were most frequent in this group. Another interesting result
in this study was that the need for intensive care was higher
in the probable group. This may have been due to the fact
that smoking and comorbidities were more frequent in this
group, and the patients in this group were older.
The values of 8 combinations of inflammatory markers
in patients with COVID-19 were calculated, and the
predicted values of these 8 ratios were compared in the
ROC analysis. The AUC values for the DFR were the highest
among the 8 combinations of inflammatory markers. The
NLR and SII were other inflammatory markers that had
higher AUC values after the DFR.
Considering both the ROC analysis and the
multivariate analysis together, the DFR and NLR are one
step ahead in terms of predicting disease severity when
compared to other hematological markers. CRP and IL-6

are inflammation-related biomarkers that have moderateto-high correlation with the NLR, and these biomarkers
are also associated with the unfavorable aspects of
COVID-19 and duration of hospitalization [59,60]. Thus,
for COVID-19, research has mostly been aimed at the
NLR, to determine if it can be used as a valuable indicator
to be able to make the decision to target the immune
system [60]. It is difficult to routinely apply IL-6 and other
cytokines in EDs or state hospitals, as they are not easily
accessible and are expensive. IN addition to the increase in
the DFR and NLR in inflammation, the fact that the NLR
is correlated with cytokines, such as IL-6, stands out in the
routine use of these combinations.
6. Conclusion
The NLR and DFR provide important prognostic
information for decision making in severe patients with
COVID-19. A high NLR, combined with the DFR, may be
a better predictor of COVID-19 than other routinely used
parameters in EDs. All patients with severe COVID-19
should be screened for hyperinflammation using the DFR
and NLR to reduce mortality. The findings herein indicated
that the parameters that they enhance from the complete
blood count, which is a simple laboratory test, can help to
identify and classify COVID-19 patients into non-severe
to severe groups. Combining these parameters with the
epidemiological data may be useful for the misdiagnosis
or nondiagnosis of COVID-19.
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